Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST).

Kolloch R, Legler UF, Champion A, Cooper-Dehoff RM, Handberg E, Zhou Q, Pepine CJ.

Eur Heart J. 2008 May;29(10):1327-34. doi: 10.1093/eurheartj/ehn123. Epub 2008 Mar 29.

2.

Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.

Bangalore S, Messerli FH, Cohen JD, Bacher PH, Sleight P, Mancia G, Kowey P, Zhou Q, Champion A, Pepine CJ; INVEST Investigators.

Am Heart J. 2008 Aug;156(2):241-7. doi: 10.1016/j.ahj.2008.02.023.

PMID:
18657652
3.

Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension.

Pepine CJ, Handberg-Thurmond E, Marks RG, Conlon M, Cooper-DeHoff R, Volkers P, Zellig P.

J Am Coll Cardiol. 1998 Nov;32(5):1228-37.

4.

Predictors of adverse outcome among patients with hypertension and coronary artery disease.

Pepine CJ, Kowey PR, Kupfer S, Kolloch RE, Benetos A, Mancia G, Coca A, Cooper-DeHoff RM, Handberg E, Gaxiola E, Sleight P, Conti CR, Hewkin AC, Tavazzi L; INVEST Investigators.

J Am Coll Cardiol. 2006 Feb 7;47(3):547-51. Epub 2006 Jan 18.

5.

Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients--findings from the International Verapamil SR/Trandolapril Study (INVEST).

Cooper-DeHoff RM, Aranda JM Jr, Gaxiola E, Cangiano JL, Garcia-Barreto D, Conti CR, Hewkin A, Pepine CJ; INVEST Investigators.

Am Heart J. 2006 May;151(5):1072-9.

PMID:
16644338
6.

Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.

Bangalore S, Messerli FH, Franklin SS, Mancia G, Champion A, Pepine CJ.

Eur Heart J. 2009 Jun;30(11):1395-401. doi: 10.1093/eurheartj/ehp109. Epub 2009 Apr 7.

7.

Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy.

Denardo SJ, Gong Y, Cooper-DeHoff RM, Farsang C, Keltai M, Szirmai L, Messerli FH, Bavry AA, Handberg EM, Mancia G, Pepine CJ.

PLoS One. 2015 Apr 2;10(4):e0122726. doi: 10.1371/journal.pone.0122726. eCollection 2015. Erratum in: PLoS One. 2016;11(6):e0157212.

9.

INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study.

Cooper-DeHoff RM, Handberg EM, Mancia G, Zhou Q, Champion A, Legler UF, Pepine CJ.

Expert Rev Cardiovasc Ther. 2009 Nov;7(11):1329-40. doi: 10.1586/erc.09.102.

10.

Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).

Cooper-Dehoff R, Cohen JD, Bakris GL, Messerli FH, Erdine S, Hewkin AC, Kupfer S, Pepine CJ; INVEST Investigators.

Am J Cardiol. 2006 Oct 1;98(7):890-4. Epub 2006 Aug 7.

PMID:
16996868
11.

Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study.

Bakris GL, Gaxiola E, Messerli FH, Mancia G, Erdine S, Cooper-DeHoff R, Pepine CJ; INVEST Investigators.

Hypertension. 2004 Nov;44(5):637-42. Epub 2004 Sep 20.

12.

Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-Trandolapril STudy (INVEST).

Zineh I, Cooper-Dehoff RM, Wessel TR, Arant CB, Sleight P, Geiser EA, Pepine CJ.

Clin Cardiol. 2005 Jul;28(7):321-8.

13.

Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension.

Reynolds NA, Wagstaff AJ, Keam SJ.

Drugs. 2005;65(13):1893-914. Review.

PMID:
16114984
14.

Predicting stroke risk in hypertensive patients with coronary artery disease: a report from the INVEST.

Coca A, Messerli FH, Benetos A, Zhou Q, Champion A, Cooper-DeHoff RM, Pepine CJ.

Stroke. 2008 Feb;39(2):343-8. Epub 2007 Dec 27.

15.

Mortality implications of angina and blood pressure in hypertensive patients with coronary artery disease: New data from extended follow-up of the International Verapamil/Trandolapril Study (INVEST).

Winchester DE, Cooper-Dehoff RM, Gong Y, Handberg EM, Pepine CJ; INVEST Investigators.

Clin Cardiol. 2013 Aug;36(8):442-7. doi: 10.1002/clc.22145. Epub 2013 May 29.

16.

A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients.

Elliott WJ, Hewkin AC, Kupfer S, Cooper-DeHoff R, Pepine CJ.

J Clin Hypertens (Greenwich). 2005 Nov;7(11):654-63.

17.

Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension.

Muijsers RB, Curran MP, Perry CM.

Drugs. 2002;62(17):2539-67. Review.

PMID:
12421112
18.

KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST).

Beitelshees AL, Gong Y, Wang D, Schork NJ, Cooper-Dehoff RM, Langaee TY, Shriver MD, Sadee W, Knot HJ, Pepine CJ, Johnson JA; INVEST Investigators.

Pharmacogenet Genomics. 2007 Sep;17(9):719-29.

19.

Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers.

Bakris GL, Cooper-Dehoff RM, Zhou Q, Kupfer S, Champion A, Pepine CJ; INVEST Investigators.

Am J Cardiovasc Drugs. 2007;7 Suppl 1:25-9.

PMID:
19845074
20.

Managing hypertension in diabetic patients--focus on trandolapril/verapamil combination.

Sharma SK, Ruggenenti P, Remuzzi G.

Vasc Health Risk Manag. 2007;3(4):453-65. Review.

Items per page

Supplemental Content

Write to the Help Desk